Do you have difficulty pouring a beverage? Drinking?
Huntington’s disease (HD) is a neurological, hereditary disease. HD has physical, emotional, behavioral,
AUSTEDO® (deutetrabenazine) tablets is a medicine to treat HD chorea. It does not treat other symptoms
The impact of HD chorea2
Chorea is the most visible symptom of HD and can affect the ability to do everyday activities. With
How much does chorea affect your daily activities?1
If you answered “yes” to one or more of these questions…
Talk to your doctor about how you can help manage your HD chorea.
Receive Important Updates
Sign up to have the latest information about AUSTEDO® tablets and HD chorea emailed to you.
You are about to leave this site
You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.
To redeem this offer, you must have a valid prescription for AUSTEDO ®. No substitutions permitted. Commercially insured patients with coverage for AUSTEDO ® may pay no out-of-pocket costs. Commercially insured patients whose insurer requires a prior authorization for AUSTEDO® may receive a 30 day supply of AUSTEDO® (up to a total of three prescriptions with only one prescription per AUSTEDO® strength or NDC) under the Program while their prior authorization is pending. If the prior authorization is approved by the commercial insurer, then the individual remains eligible for the Program. If the prior authorization is denied by the commercial insurer, then the individual is no longer eligible for this Program and may not receive any additional Program benefits. Maximum annual benefits apply and out-of-pocket expenses may vary. Patient is responsible for costs above maximum benefit amounts. If you have any questions regarding your eligibility or benefits, please call the AUSTEDO ® Copay Program at 1-800-887-8100.
You are not eligible for this offer if your prescriptions are paid for in part or full by any state or federally funded programs, including but not limited to Medicare or Medicaid, Medigap, VA, DOD, TRICARE, or by private health benefit programs which reimburse you for the entire cost of your prescription drugs. This offer is not valid for patients who are Medicare eligible and are enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees (i.e., patients who are eligible for Medicare Part D but receive a prescription drug benefit through a former employer). You are not eligible for this offer if you are uninsured or a cash-paying patient. This offer is void in California if an AB-rated generic drug is available for the product. By redeeming this offer, you acknowledge that you are an eligible patient and you understand and agree to comply with the terms and if copied, transferred, purchased, altered or traded and where prohibited and restricted by law. conditions of this offer. Void if copied, transferred, purchased, altered or traded and where prohibited and restricted by law. Program managed by PSKW, LLC on behalf of Teva Pharmaceuticals. The parties reserve the right to change or discontinue this offer at any time without notice. This offer is not health insurance.
This offer is restricted to residents of the United States and Puerto Rico and valid only at participating pharmacies. This offer is limited to one per customer and may not be used with any other discount, coupon or offer. Offer expires December 31, 2019.To the Pharmacist:
When you apply this offer, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental program for this prescription.
Pharmacist Instructions: Submit claim to Therapy First Plus. If primary coverage exists, input offer information as secondary coverage and transmit using the COB segment of the NCPDP transaction.
For questions regarding processing, please call the Help Desk 1-800-422-5604 .
AUS-41403 December 2018
Are you a healthcare professional?
The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?
AUSTEDO® is a prescription medicine that is used to treat:
It is not known if AUSTEDO® is safe and effective in children.
Important Safety Information
AUSTEDO® can cause serious side effects in people with Huntington’s disease, including: depression, suicidal thoughts, or suicidal actions. Do not start taking AUSTEDO® if you are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts or feelings. This is especially important when AUSTEDO® is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of suicide.
- have Huntington’s disease and are depressed or have thoughts of suicide.
- have liver problems.
- are taking a monoamine oxidase inhibitor (MAOI) medicine. Do not take an MAOI within 14 days after you stop taking AUSTEDO®. Do not start AUSTEDO® if you stopped taking an MAOI in the last 14 days. Ask your healthcare provider or pharmacist if you are not sure.
- are taking reserpine. Do not take medicines that contain reserpine (such as Serpalan® and Renese®-R) with AUSTEDO®. If your healthcare provider plans to switch you from taking reserpine to AUSTEDO®, you must wait at least 20 days after your last dose of reserpine before you start taking AUSTEDO®.
- are taking tetrabenazine (Xenazine®). If your healthcare provider plans to switch you from tetrabenazine (Xenazine®) to AUSTEDO®, take your first dose of AUSTEDO® on the day after your last dose of tetrabenazine (Xenazine®).
- are taking valbenazine (Ingrezza®).
- Irregular heartbeat (QT prolongation). AUSTEDO® increases your chance of having certain changes in the electrical activity in your heart. These changes can lead to a dangerous abnormal heartbeat. Taking AUSTEDO® with certain medicines may increase this chance. If you are at risk of QT prolongation, your healthcare provider should check your heart before and after increasing your AUSTEDO® dose above 24 mg a day.
- Neuroleptic Malignant Syndrome. Call your healthcare provider right away and go to the nearest emergency room if you develop these signs and symptoms that do not have another obvious cause: high fever, stiff muscles, problems thinking, very fast or uneven heartbeat, or increased sweating.
- Restlessness. You may get a condition where you feel a strong urge to move. This is called akathisia.
- Parkinsonism in people with Huntington’s disease. Symptoms include: slight shaking, body stiffness, trouble moving, or keeping your balance.
Sleepiness (sedation) is a common side effect of AUSTEDO®. While taking AUSTEDO®, do not drive a car or operate dangerous machinery until you know how AUSTEDO® affects you. Drinking alcohol and taking other drugs that may also cause sleepiness while you are taking AUSTEDO® may increase any sleepiness caused by AUSTEDO®.
The most common side effects of AUSTEDO® in people with Huntington’s disease include sleepiness (sedation), diarrhea, tiredness, and dry mouth.
The most common side effects of AUSTEDO® in people with tardive dyskinesia include inflammation of the nose and throat (nasopharyngitis) and problems sleeping (insomnia).
These are not all the possible side effects of AUSTEDO®. Call your doctor for medical advice about side effects. You may report side effects to
FDA at 1-800-FDA-1088.
Please read the accompanying Medication Guide.
References: 1. Nance M, Paulsen JS, Rosenblatt A, Wheelock V. A physician’s guide to the management of Huntington’s disease. 3rd ed. Huntington’s Disease Society of America (HDSA) website. http://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf. Published 2011. Accessed February 9, 2017. 2. Huntington’s disease: a family guide. HDSA website. http://hdsa.org/wp-content/uploads/2015/03/HDSA_FamilyGuide.pdf. Published 2016. Accessed January 6, 2017.